# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Friedrich Nietzsche (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI019-SYN
- Date: 2026-07-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Konrad Ellison-Mbatha, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review of the headache diary, the MRI and the eye examination, seen the same day by headache medicine. **S**

## History of present illness

Mr. Nietzsche returns with his 14-day headache diary, after an MRI and blood tests this morning and a comprehensive eye examination, and is seen by Dr. Achterberg-Sato of headache medicine on the same day. His diary shows headache on 10 of 14 days. On 7 of them the pain was moderate or severe, throbbing, mostly over the right forehead and eye, worse with walking uphill or reading, with light and noise sensitivity and nausea, and vomiting on 3; it lasted from six hours to most of two days. On the other 3 days the headache was a milder pressure across the forehead. He has had no visual or other aura. He took the butalbital combination on 9 days, two or three tablets each time, and ibuprofen on 2 more, so acute medicine on 11 of 14 days. By his account he has had headache on about 20 days a month for at least eight months, and has taken the combination tablets on most of those days. He has slept four to five hours a night. He has had no weakness, numbness, fever or change in his usual vision. **S**

| Element | Detail |
|---|---|
| Diary | Headache on 10 of 14 days, 7 with migraine features; vomiting on 3; no aura |
| Acute medicine | Butalbital combination on 9 days, ibuprofen on 2: 11 of 14 days |
| Duration of the pattern | About 20 headache days a month for at least eight months |
| MRI | Normal brain; high myopia of the globes |
| Syphilis serology | Treponemal antibody 0.12 (nonreactive); RPR nonreactive |
| Eye examination | Pathologic myopia of the right eye; no retinal break; pressures 15 and 14 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight loss |
| Eyes | Positive | Poor right eye as always; tired eyes when reading; no new visual loss, flashes or floaters |
| Gastrointestinal | Positive | Nausea with attacks, vomiting on 3 days; occasional constipation |
| Neurological | Positive | Headaches as in the diary; no weakness, numbness, speech change or aura |
| Psychiatric | Negative | Frustrated by lost working days; no hopelessness or thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, scheduled taper: one tablet twice a day for 7 days, then one tablet a day for 7 days, then one tablet every other day for 7 days, then stop **S**
- Naproxen 500 mg oral tablet, one tablet with food at the start of a migraine attack, may repeat once after 12 hours; no more than two days a week **S**
- Metoclopramide 10 mg oral tablet, one tablet with the acute medicine when a migraine attack brings nausea or vomiting; no more than two days a week **S**
- Galcanezumab 120 mg/mL auto-injector, 240 mg (two injections) under the skin as a first loading dose, then 120 mg once a month, for chronic migraine prevention **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/74 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 98% on room air; weight 66.2 kg; BMI 21.9 kg/m². All vital signs are synthetic.

Treponemal antibody (immunoassay index): 0.12; Intraocular pressure, right eye: 15 mmHg; Intraocular pressure, left eye: 14 mmHg. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Comfortable today; blood pressure 116/74, pulse 66 |
| Eyes | Right pupil about 1 mm larger than the left in light and dark, both reacting briskly, no afferent defect, no ptosis; eye movements full; at the eye examination today, best corrected vision 20/100 right and 20/20 left, refraction about -13.50 right and -6.25 left, pressures 15 and 14 mmHg, and on dilated examination a tilted right disc with peripapillary atrophy, a posterior staphyloma and patchy chorioretinal atrophy at the right macula, no choroidal neovascularization on OCT, a tessellated left fundus, and no retinal breaks or lattice in either eye |
| Neurological | Cranial nerves otherwise normal; strength, sensation, reflexes, coordination and gait normal; no papilledema |
| Head and neck | Tenderness of the right occipital and neck muscles; temporal arteries normal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic migraine without aura** (G43.709). Dr. Achterberg-Sato confirms chronic migraine by ICHD-3 criteria: headache on 15 or more days a month for more than three months, with migraine features on at least 8 days a month. The MRI with and without contrast shows no structural cause, including no mass behind the right eye, and the neurological examination is normal. Syphilis serology drawn this morning is nonreactive, so infection does not explain the unequal pupils, which date from early childhood, or the poor right eye, which the eye examination explains. With about 20 headache days a month and a MIDAS of 74, prevention is indicated. **S**
   - Galcanezumab 240 mg loading dose given today, then 120 mg every four weeks.
   - Naproxen 500 mg with metoclopramide 10 mg early in an attack, no more than two days a week.
   - Sumatriptan to be added once the taper is complete.
2. **Medication overuse headache** (G44.40). Regular use of a combination analgesic on 10 or more days a month for more than three months, with headache on 15 or more days, meets ICHD-3 criteria for medication overuse headache. Butalbital is a barbiturate and is tapered rather than stopped abruptly. **S**
   - Stop ibuprofen; replace as-needed combination tablets with a scheduled three-week taper: one tablet twice a day for a week, once a day for a week, every other day for a week, then stop.
   - Expect worse headache for one to two weeks; call the same day for tremor, sweating, agitation, confusion or a seizure.
   - Nurse phone check at the end of the first taper week.
3. **Pathologic myopia of the right eye** (H44.2E1). Myopic macular atrophy explains the long-standing poor vision in the right eye; there is no choroidal neovascularization or retinal break. The difference of about seven dioptres between the eyes makes spectacles uncomfortable. **S**
   - Contact lens fitting for both eyes.
   - Amsler grid for the right eye weekly.
   - Same-day eye care for new flashes, a shower of floaters, a shadow or distorted vision.
4. **Chronic insomnia** (G47.00). Four to five hours of sleep; no sedatives are to be added. **S**
   - CBT-I through the clinic's behavioral sleep program, starting next week.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Red-flag screen (SNNOOP10): systemic signs, neurological signs, sudden onset, onset after 50, change in pattern, positional or Valsalva features, papilledema, progressive course | Every visit | Completed today | Strong right-sided predominance and a change in frequency prompted imaging; MRI normal; no other red flags; no papilledema |
| Survey | Headache diary: headache days, migraine days, attack features, triggers | Every visit | Completed today | 14 days kept: headache on 10, migraine features on 7; about 20 headache days a month by history for at least eight months |
| Medication safety | Acute-medicine days (overuse limits: combination analgesics, triptans fewer than 10 days a month, simple analgesics fewer than 15) | Every visit | Completed today | Acute medicine on 11 of 14 days: butalbital combination on 9, ibuprofen on 2 |
| Imaging | MRI of the brain with and without contrast | Once, for the change in frequency, strong right-sided predominance, unequal pupils and a poor right eye | Completed today | Done this morning: normal brain, pituitary and optic nerves; elongated globes with a right posterior staphyloma |
| Laboratory | Syphilis serology (treponemal immunoassay and RPR) | Once, at diagnosis | Completed today | Drawn this morning: treponemal antibody 0.12 (nonreactive) and RPR nonreactive; no lumbar puncture needed |
| Examination | Comprehensive eye examination: refraction, pupils, pressure, dilated fundus examination, macular OCT | At diagnosis, then yearly for pathologic myopia, and urgently for new flashes, floaters or a shadow | Completed today | Pathologic myopia of the right eye with macular atrophy; no neovascularization or retinal break; intraocular pressure 15 mmHg right and 14 mmHg left |
| Medication safety | Barbiturate withdrawal: tremor, sweating, agitation, insomnia, confusion, seizures; rebound headache | During the three-week taper and at the first visit after it | Completed today | Before the taper: no history of seizures, no alcohol excess and no other sedatives; taper explained in writing |
| Medication safety | Galcanezumab tolerability: injection sites, constipation, blood pressure, hypersensitivity | Before starting and at each injection visit | Completed today | Before the first dose: blood pressure 116/74; no allergy; occasional constipation noted; injection technique taught and the loading dose given in clinic |
| Examination | Preventive efficacy (at least 50% fewer monthly migraine days; headache days below 15 a month) | At three months on treatment | Due | Galcanezumab started today; efficacy judged at about three months |
| Survey | Disability (MIDAS, recorded as its five items, and HIT-6) | At baseline and after two to three months of treatment | Up to date | MIDAS 74 (grade IV) and HIT-6 68 at intake; repeat at about two to three months |
| Survey | Mood (PHQ-9) and anxiety (GAD-7), with direct questions about hopelessness and self-harm | At baseline and at two to three months; questions at every visit | Up to date | PHQ-9 7 and GAD-7 6 at intake; no hopelessness or thoughts of self-harm today |
| Self-management | Sleep: hours, sleep diary, insomnia severity; no sedative sleeping tablets | Every visit | Ordered | Four to five hours a night; CBT-I booked to start next week |
| Self-management | Reading, writing and walking plan | Every visit | Completed today | Reading in short spells with breaks; daily walks continue |
| Referral | Headache medicine consultation | At diagnosis | Completed today | Seen by Dr. Achterberg-Sato today |

## Goal progress

- A two-week headache diary and the tests that allow a firm diagnosis. Outcome by 2026-07-21: Diary of 14 days kept; ICHD-3 criteria for chronic migraine and medication overuse headache met; MRI normal; syphilis serology nonreactive. **S**
- Stop the butalbital combination safely. In progress; target 2026-08-18. **S**
- Fewer than 15 headache days a month, and at least half as many migraine days, within three months of starting prevention. In progress; target 2026-10-13. **S**
- Acute medicine on no more than eight days a month after withdrawal. In progress; target 2026-09-15. **S**
- Clear vision in the left eye for reading and protection of the right eye. In progress; target 2026-08-18. **S**
- Six and a half hours of sleep on most nights without sleeping tablets. In progress; target 2026-10-13. **S**

## Medication changes

- Stopped: Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, one or two tablets as needed for headache, taken on about 16 days a month, up to four tablets a day (prescribed abroad) **S**
- Stopped: Ibuprofen 200 mg oral tablet, two tablets as needed for headache on days without the combination tablets, about 4 days a month (over the counter) **S**
- Started: Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, scheduled taper: one tablet twice a day for 7 days, then one tablet a day for 7 days, then one tablet every other day for 7 days, then stop **S**
- Started: Naproxen 500 mg oral tablet, one tablet with food at the start of a migraine attack, may repeat once after 12 hours; no more than two days a week **S**
- Started: Metoclopramide 10 mg oral tablet, one tablet with the acute medicine when a migraine attack brings nausea or vomiting; no more than two days a week **S**
- Started: Galcanezumab 120 mg/mL auto-injector, 240 mg (two injections) under the skin as a first loading dose, then 120 mg once a month, for chronic migraine prevention **S**

## Guideline basis

- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018), International Headache Society (Cephalalgia 2018;38(1):1-211)
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021), American Headache Society (Headache 2021;61(7):1021-1039)
- Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024), American Headache Society (Headache 2024;64(4):333-341)
- European Academy of Neurology guideline on the management of medication-overuse headache (2020), European Academy of Neurology (European Journal of Neurology 2020;27(7):1102-1116)
- European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update (2022), European Headache Federation (Journal of Headache and Pain 2022;23(1):67)
- Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013), American Headache Society (Headache 2013;53(10):1651-1659)
- Sexually Transmitted Infections Treatment Guidelines, 2021 (2021), Centers for Disease Control and Prevention (MMWR Recommendations and Reports 2021;70(4):1-187)
- Refractive Errors Preferred Practice Pattern (2023), American Academy of Ophthalmology (Ophthalmology 2023;130(3):P1-P60)
- Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern (2026), American Academy of Ophthalmology (Ophthalmology 2026;133(4):P202-P236)
- Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline (2021), American Academy of Sleep Medicine (Journal of Clinical Sleep Medicine 2021;17(2):255-262)

## Follow-up

- Nurse phone check at the end of the first taper week. Four-week review with the second galcanezumab injection. Call the same day for withdrawal symptoms, a headache unlike his usual attacks, weakness, numbness, fever, or new flashes or floaters. **S**
- Next scheduled visit 2026-08-18: four-week review after starting galcanezumab and the taper: withdrawal, headache days, acute medicine and the second injection. **S**
